1976 related articles for article (PubMed ID: 26026974)
21. Germline mutations in BRCA1 and BRCA2 in breast-ovarian families from a breast cancer risk evaluation clinic.
Martin AM; Blackwood MA; Antin-Ozerkis D; Shih HA; Calzone K; Colligon TA; Seal S; Collins N; Stratton MR; Weber BL; Nathanson KL
J Clin Oncol; 2001 Apr; 19(8):2247-53. PubMed ID: 11304778
[TBL] [Abstract][Full Text] [Related]
22. Low prevalence of BRCA1 and BRCA2 mutations in the sporadic breast cancer of Spanish population.
de Juan Jiménez I; Esteban Cardeñosa E; Palanca Suela S; Barragán González E; Aznar Carretero I; Munárriz Gandía B; Santaballa Bertran A; Torregrosa Maicas MD; Guillén Ponce C; Sánchez Heras AB; Bayón Lara A; Fuster Lluch O; Bolufer Gilabert P
Fam Cancer; 2012 Mar; 11(1):49-56. PubMed ID: 21918853
[TBL] [Abstract][Full Text] [Related]
23. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
[TBL] [Abstract][Full Text] [Related]
24. BRCA1 Gene Mutation Screening for the Hereditary Breast and/or Ovarian Cancer Syndrome in Breast Cancer Cases: a First High Resolution DNA Melting Analysis in Indonesia.
Mundhofir FE; Wulandari CE; Prajoko YW; Winarni TI
Asian Pac J Cancer Prev; 2016; 17(3):1539-46. PubMed ID: 27039803
[TBL] [Abstract][Full Text] [Related]
25. Identification of germline BRCA1 mutations among breast cancer families in Northeastern Iran.
Kooshyar MM; Nassiri M; Mahdavi M; Doosti M; Parizadeh A
Asian Pac J Cancer Prev; 2013; 14(7):4339-45. PubMed ID: 23992000
[TBL] [Abstract][Full Text] [Related]
26. Clinical and pathologic characteristics of BRCA-positive and BRCA-negative male breast cancer patients: results from a collaborative multicenter study in Italy.
Ottini L; Silvestri V; Rizzolo P; Falchetti M; Zanna I; Saieva C; Masala G; Bianchi S; Manoukian S; Barile M; Peterlongo P; Varesco L; Tommasi S; Russo A; Giannini G; Cortesi L; Viel A; Montagna M; Radice P; Palli D
Breast Cancer Res Treat; 2012 Jul; 134(1):411-8. PubMed ID: 22527108
[TBL] [Abstract][Full Text] [Related]
27. CCND1 and ZNF217 gene amplification is equally frequent in BRCA1 and BRCA2 associated and non-BRCA breast cancer.
Plevova P; Cerna D; Balcar A; Foretova L; Zapletalova J; Silhanova E; Curik R; Dvorackova J
Neoplasma; 2010; 57(4):325-32. PubMed ID: 20429623
[TBL] [Abstract][Full Text] [Related]
28. BRCA1/BRCA2 mutations in Japanese women with ductal carcinoma in situ.
Liu Y; Ide Y; Inuzuka M; Tazawa S; Kanada Y; Matsunaga Y; Kuwayama T; Sawada T; Akashi-Tanaka S; Nakamura S
Mol Genet Genomic Med; 2019 Mar; 7(3):e493. PubMed ID: 30652428
[TBL] [Abstract][Full Text] [Related]
29. Frequency of 5382insC mutation of BRCA1 gene among breast cancer patients: an experience from Eastern India.
Chakraborty A; Mukhopadhyay A; Bhattacharyya D; Bose CK; Choudhuri K; Mukhopadhyay S; Basak J
Fam Cancer; 2013 Sep; 12(3):489-95. PubMed ID: 23232912
[TBL] [Abstract][Full Text] [Related]
30. Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ovarian cancer.
Gutiérrez-Enríquez S; de la Hoya M; Martínez-Bouzas C; Sanchez de Abajo A; Ramón y Cajal T; Llort G; Blanco I; Beristain E; Díaz-Rubio E; Alonso C; Tejada MI; Caldés T; Diez O
Breast Cancer Res Treat; 2007 May; 103(1):103-7. PubMed ID: 17063271
[TBL] [Abstract][Full Text] [Related]
31. Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families.
Buffone A; Capalbo C; Ricevuto E; Sidoni T; Ottini L; Falchetti M; Cortesi E; Marchetti P; Scambia G; Tomao S; Rinaldi C; Zani M; Ferraro S; Frati L; Screpanti I; Gulino A; Giannini G
Breast Cancer Res Treat; 2007 Dec; 106(2):289-96. PubMed ID: 17333342
[TBL] [Abstract][Full Text] [Related]
32. Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1.
Miramar MD; Calvo MT; Rodriguez A; Antón A; Lorente F; Barrio E; Herrero A; Burriel J; García de Jalón A
Breast Cancer Res Treat; 2008 Nov; 112(2):353-8. PubMed ID: 18176857
[TBL] [Abstract][Full Text] [Related]
33. Phenotypic analysis of familial breast cancer: comparison of BRCAx tumors with BRCA1-, BRCA2-carriers and non-familial breast cancer.
Aloraifi F; Alshehhi M; McDevitt T; Cody N; Meany M; O'Doherty A; Quinn CM; Green AJ; Bracken A; Geraghty JG
Eur J Surg Oncol; 2015 May; 41(5):641-6. PubMed ID: 25736863
[TBL] [Abstract][Full Text] [Related]
34. Prevalence of BRCA1 and BRCA2 pathogenic and likely pathogenic variants in non-selected ovarian carcinoma patients in Brazil.
Cotrim DP; Ribeiro ARG; Paixão D; de Queiroz Soares DC; Jbili R; Pandolfi NC; Cezana C; de Cássia Mauro C; Mantoan H; Bovolim G; de Brot L; Torrezan GT; Carraro DM; Baiocchi G; da Cruz Formiga MN; da Costa AABA
BMC Cancer; 2019 Jan; 19(1):4. PubMed ID: 30606148
[TBL] [Abstract][Full Text] [Related]
35. The importance of analysis of long-range rearrangement of BRCA1 and BRCA2 in genetic diagnosis of familial breast cancer.
Kwong A; Chen J; Shin VY; Ho JC; Law FB; Au CH; Chan TL; Ma ES; Ford JM
Cancer Genet; 2015 Sep; 208(9):448-54. PubMed ID: 26271414
[TBL] [Abstract][Full Text] [Related]
36. Germline mutations in BRCA1 and BRCA2 in epithelial ovarian cancer patients in Brazil.
Maistro S; Teixeira N; Encinas G; Katayama ML; Niewiadonski VD; Cabral LG; Ribeiro RM; Gaburo Junior N; de Gouvêa AC; Carraro DM; Sabino EC; Diz MD; Chammas R; de Bock GH; Folgueira MA
BMC Cancer; 2016 Dec; 16(1):934. PubMed ID: 27914478
[TBL] [Abstract][Full Text] [Related]
37. Absence of genomic BRCA1 and BRCA2 rearrangements in Ashkenazi breast and ovarian cancer families.
Stadler ZK; Saloustros E; Hansen NA; Schluger AE; Kauff ND; Offit K; Robson ME
Breast Cancer Res Treat; 2010 Sep; 123(2):581-5. PubMed ID: 20221693
[TBL] [Abstract][Full Text] [Related]
38. Molecular characterization and clinical interpretation of BRCA1/BRCA2 variants in families from Murcia (south-eastern Spain) with hereditary breast and ovarian cancer: clinical-pathological features in BRCA carriers and non-carriers.
Gabaldó Barrios X; Sarabia Meseguer MD; Marín Vera M; Sánchez Bermúdez AI; Macías Cerrolaza JA; Sánchez Henarejos P; Zafra Poves M; García Hernández MR; Cuevas Tortosa E; Aliaga Baño Á; Castillo Guardiola V; Martínez Hernández P; Tovar Zapata I; Martínez Barba E; Ayala de la Peña F; Alonso Romero JL; Noguera Velasco JA; Ruiz Espejo F
Fam Cancer; 2017 Oct; 16(4):477-489. PubMed ID: 28477318
[TBL] [Abstract][Full Text] [Related]
39. BRCA1 and BRCA2 germline mutations screening in Algerian breast/ovarian cancer families.
Cherbal F; Bakour R; Adane S; Boualga K; Benais-Pont G; Maillet P
Dis Markers; 2010; 28(6):377-84. PubMed ID: 20683152
[TBL] [Abstract][Full Text] [Related]
40. A population-based analysis of germline BRCA1 and BRCA2 testing among ovarian cancer patients in an era of histotype-specific approaches to ovarian cancer prevention.
Hanley GE; McAlpine JN; Miller D; Huntsman D; Schrader KA; Blake Gilks C; Mitchell G
BMC Cancer; 2018 Mar; 18(1):254. PubMed ID: 29506471
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
